Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 03-2015 | 03-2014 | 03-2013 | 03-2012 | 03-2011 | |
| Sales | 16,178,200 | 16,916,850 | 18,842,930 | 19,163,430 | 17,101,020 |
| Cost of Goods | 4,741,009 | 4,902,630 | 5,416,290 | 5,501,560 | 3,826,280 |
| Gross Profit | 11,437,190 | 12,014,220 | 13,426,630 | 13,661,870 | 13,274,730 |
| Operating Expenses | 12,613,410 | 10,622,120 | 11,944,610 | 10,296,580 | 8,852,310 |
| Operating Income | -1,176,211 | 1,392,740 | 1,482,320 | 3,365,850 | 4,422,709 |
| Interest Expense | 299,190 | 307,200 | 40,200 | 23,910 | 16,080 |
| Other Income | 151,924 | 502,970 | 127,330 | -135,470 | 70,141 |
| Pre-tax Income | -1,323,477 | 1,588,510 | 1,569,450 | 3,206,470 | 4,476,770 |
| Income Tax | -21,867 | 492,920 | -46,940 | 1,590,120 | 1,461,740 |
| Net Income Continuous | -1,301,609 | 1,095,590 | 2,406,180 | 1,806,562 | 2,934,118 |
| Minority Interests | 24,943 | 29,000 | N/A | N/A | N/A |
| Net Income | $-1,326,552 | $1,066,580 | $1,588,050 | $1,576,850 | $2,986,360 |
| EPS Basic Total Ops | -0.84 | 0.68 | 1.18 | 1.00 | 1.84 |
| EPS Basic Continuous Ops | -0.83 | 0.69 | 1.52 | 1.14 | 1.86 |
| EPS Diluted Total Ops | -0.84 | 0.67 | 1.18 | 1.00 | 1.84 |
| EPS Diluted Continuous Ops | -0.83 | 0.69 | 1.52 | 1.14 | 1.86 |
| EBITDA(a) | $1,198,442 | $3,550,160 | $3,915,700 | $4,991,030 | $15,748,510 |